Get the Stockscreener App
1.03
7.63%
0.073
Ovid Therapeutics Inc stock is traded at $1.03, with a volume of 1.17M.
It is up +7.63% in the last 24 hours and up +53.98% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$0.957
Open:
$0.96
24h Volume:
1.17M
Relative Volume:
0.69
Market Cap:
$73.24M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.3733
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+6.19%
1M Performance:
+53.98%
6M Performance:
+66.80%
1Y Performance:
-14.88%
1-Day Range:
$0.94
$1.0863
1-Week Range:
$0.84
$1.0863
52-Week Range:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.03 | 66.33M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Technical Models Detect Momentum Build in Ovid Therapeutics Inc.2025 Market Sentiment & Fast Gain Swing Alerts - thegnnews.com
Spotlight On 3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - MSN
BTIG Assigns Buy Rating to Ovid Therapeutics with $4 Price Target - AInvest
Is Ovid Therapeutics Inc. Forming a Bottom PatternJuly 2025 News Drivers & Low Risk Entry Point Tips - beatles.ru
Top Analysts Recommend 3 Strong Buys: Palo Alto Networks, Ovid Therapeutics, and Blaize Holdings - AInvest
Analyzing Ovid Therapeutics Inc. with risk reward ratio charts2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
How high can Ovid Therapeutics Inc. stock go2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
Ovid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street Zen - Defense World
Has Ovid Therapeutics Inc. formed a bullish divergenceJuly 2025 Rallies & Safe Capital Allocation Plans - Newser
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - 富途牛牛
What makes Ovid Therapeutics Inc. stock price move sharplyJobs Report & Verified Chart Pattern Signals - Newser
Ovid Therapeutics Surges 11.88% on Royalty Sale and Analyst Upgrades: Is This a Short-Term Rally or a New Trend? - AInvest
Ovid Therapeutics (OVID) up more than 100% since Aug 4 - AInvest
Analyzing Ovid Therapeutics Inc. with multi timeframe chartsAnalyst Upgrade & Community Verified Watchlist Alerts - Newser
Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Tools to monitor Ovid Therapeutics Inc. recovery probabilityDividend Hike & Smart Money Movement Alerts - Newser
Ovid Therapeutics Plunges 11.42% on Q2 Loss, Pipeline Progress - AInvest
Ovid Therapeutics 2025 Q2 Earnings Sharp Earnings Decline Amid Revenue Surge - AInvest
B.Riley Financial Initiates Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $3 - 富途牛牛
Ovid Therapeutics shares fall 6.76% premarket after reporting business updates and second quarter results. - AInvest
Ovid Therapeutics Reports Increased Revenue Amid Challenges - TipRanks
Ovid Therapeutics Q2 Earnings: Revenue Up, Net Loss Widens - AInvest
Ovid Therapeutics (OVID) up more than 100% since Jul 17 - AInvest
Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement. - AInvest
Ovid Therapeutics Reports Q2 2025 Results: $38.3M Cash, $6.3M Revenue, Net Loss of $4.7M - AInvest
Ovid Therapeutics Surges 36.76%: What's Fueling the Biotech Breakout? - AInvest
Ovid Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Ovid Therapeutics Soars 24.99%—What’s Fueling This Biotech Breakout? - AInvest
Ovid Therapeutics: Navigating the Maze of Rare Disease Innovation and Financial Constraints - AInvest
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Q2 2025 Financials, $7mln Royalty Deal, Q3 2025 Results Expected - AInvest
Ovid Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results | OVID Stock News - GuruFocus
Ovid Therapeutics Reports Business Updates and Second Quarter 20 - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Ovid's Next-Gen Epilepsy Drug Nears Key Data as Company Strengthens Cash Position with $7M Deal - Stock Titan
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ovid Therapeutics initiated with a Buy at Lucid Capital - TipRanks
How to track smart money flows in Ovid Therapeutics Inc.Exit Point & Weekly Watchlist for Hot Stocks - Newser
Will Ovid Therapeutics Inc. price bounce be sustainableSwing Entry Insight With Forecast Accuracy - Newser
Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% – Here’s Why - Defense World
Is Ovid Therapeutics Inc. stock poised for growthFree Watchlist for Low Risk High Return - Newser
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics OVID 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi. - AInvest
Ovid Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating - Investing.com Australia
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):